Mahmoud Othman Aboudeif
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mahmoud Othman Aboudeif has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Ashraf Abd El Reheem
Anaesthesia Department, Cairo University, Giza, Egypt
1 shared publication - Baher Matta Hanna
Department of Pediatrics, Faculty of Medicine, Cairo University, Egypt
1 shared publication - Dina Khedr
Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt
1 shared publication - Fatma Al Zahraa Mostafa
Department of Pediatrics, Faculty of Medicine, Cairo University, Egypt
1 shared publication - Marwa Ahmed Sedkey
Cairo University, Giza, Egypt
1 shared publication Mohamad Abd ElMeguid
Cardiology Department, Cairo University, Giza, Egypt
1 shared publication
Latest Publications
- Open Access
- 14 October 2026
- Published by Springer Nature in Egyptian Pediatric Association Gazette
- Vol. 74 (1) , 131
Is liposomal iron superior in treating anemic children with congenital acyanotic heart diseases? A randomized controlled clinical trial
Background: Children with congenital heart disease (CHD) often suffer from Iron deficiency anemia (IDA), which is linked to poorer clinical outcomes. Liposomal iron has been proposed as a promising advancement in iron supplementation across diverse populations. This study compared the efficacy as measured by changes in hemoglobin from baseline to end of study, and the tolerability of liposomal and conventional iron, with an emphasis on some clinical outcomes. Methods: A randomized, double-blind, controlled clinical trial was conducted at Cairo University Children’s Hospital (CUCH). Sixty-seven children aged 6 months to 12 years with clinically stable children with hemodynamically insignificant acyanotic congenital heart disease (ACHD) and mild-to-moderate IDA were included. Patients were randomly assigned to one of the treatment regimens: oral iron hydroxide polymaltose complex (3 mg/kg/day) or oral liposomal iron (1 mg/kg/day) for four weeks. A nutritional assessment was performed, and hematological and iron indices were evaluated. Results: After four weeks of iron supplementation, the percentage changes in Hb ( p = 0.137) and other hematological and iron indices did not differ between the two intervention groups, except for greater improvement in anemia severity grading in the liposomal iron group ( p = 0.05). A lower incidence of constipation ( p = 0.015) and metallic taste ( p = 0.007) was reported in the liposomal iron group. Conclusions: No significant difference was observed between the two treatment groups in Hb levels and other hematological and iron indices after four weeks of treatment. However, fewer adverse effects were reported in the liposomal iron group. Registry: PACTR, TRN: PACTR202501496307274, and date of registration: January 23, 2025.
- 14 October 2026
- Published by Springer Nature in Egyptian Pediatric Association Gazette
- Vol. 74 (1) , 131
Open AccessIs liposomal iron superior in treating anemic children with congenital acyanotic heart diseases? A randomized controlled clinical trial
Background: Children with congenital heart disease (CHD) often suffer from Iron deficiency anemia (IDA), which is linked to poorer clinical outcomes. Liposomal iron has been proposed as a promising advancement in iron supplementation across diverse populations. This study compared the efficacy as measured by changes in hemoglobin from baseline to end of study, and the tolerability of liposomal and conventional iron, with an emphasis on some clinical outcomes. Methods: A randomized, double-blind, controlled clinical trial was conducted at Cairo University Children’s Hospital (CUCH). Sixty-seven children aged 6 months to 12 years with clinically stable children with hemodynamically insignificant acyanotic congenital heart disease (ACHD) and mild-to-moderate IDA were included. Patients were randomly assigned to one of the treatment regimens: oral iron hydroxide polymaltose complex (3 mg/kg/day) or oral liposomal iron (1 mg/kg/day) for four weeks. A nutritional assessment was performed, and hematological and iron indices were evaluated. Results: After four weeks of iron supplementation, the percentage changes in Hb ( p = 0.137) and other hematological and iron indices did not differ between the two intervention groups, except for greater improvement in anemia severity grading in the liposomal iron group ( p = 0.05). A lower incidence of constipation ( p = 0.015) and metallic taste ( p = 0.007) was reported in the liposomal iron group. Conclusions: No significant difference was observed between the two treatment groups in Hb levels and other hematological and iron indices after four weeks of treatment. However, fewer adverse effects were reported in the liposomal iron group. Registry: PACTR, TRN: PACTR202501496307274, and date of registration: January 23, 2025.
- 23 August 2024
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 37 (10) , 875-884
The role of Cardiotrophin-1 and echocardiography in early detection of subclinical diabetic cardiomyopathy in children and adolescents with type 1 diabetes mellitus
Objectives: To assess the role of Cardiotrophin-1 (CT-1) and echocardiography in early detection of subclinical Diabetic Cardiomyopathy (DCM) in children with type 1 Diabetes Mellitus (T1D). Methods: This case-control study included two groups of children and adolescents aged between 7 and 18. Group (1) included forty patients with T1D (duration > 5 years) regularly followed at the children's hospital of Cairo University, and Group (2) included forty age and sex-matched healthy subjects as a control group. The serum level of CT-1 was measured, and conventional echocardiography, tissue Doppler imaging (TDI), and 2D speckle tracking echocardiography were performed. Results: The level of CT-1 in the cases ranged from 11 to 1039.4 pg/ml with a median (IQR) of 19.4 (16.60–25.7) pg/ml, while its level in the control group ranged from 10.8 to 162.6 pg/ml with a median (IQR) of 20.2 (16.2–24.8) pg/ml. CT-1 levels showed no statistically significant difference between cases and controls. Patients had significantly higher mean left ventricle E/E′ ratio (p<0.001), lower mean 2D global longitudinal strain (GLS) of the left ventricle (LV) (p<0.001), and lower mean GLS of the right ventricle (RV) (p<0.001) compared to controls. Ofpatients with diabetes, 75 % had LV diastolic dysfunction, 85 % had RV diastolic dysfunction, 97.5 % had LV systolic dysfunction, and 100 % had RV systolic dysfunction. Conclusions: Non-conventional echocardiography is important for early perception of subclinical DCM in patients with T1D. CT-1 was not specific for early detection of DCM.
- 23 August 2024
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 37 (10) , 875-884
The role of Cardiotrophin-1 and echocardiography in early detection of subclinical diabetic cardiomyopathy in children and adolescents with type 1 diabetes mellitus
Objectives: To assess the role of Cardiotrophin-1 (CT-1) and echocardiography in early detection of subclinical Diabetic Cardiomyopathy (DCM) in children with type 1 Diabetes Mellitus (T1D). Methods: This case-control study included two groups of children and adolescents aged between 7 and 18. Group (1) included forty patients with T1D (duration > 5 years) regularly followed at the children's hospital of Cairo University, and Group (2) included forty age and sex-matched healthy subjects as a control group. The serum level of CT-1 was measured, and conventional echocardiography, tissue Doppler imaging (TDI), and 2D speckle tracking echocardiography were performed. Results: The level of CT-1 in the cases ranged from 11 to 1039.4 pg/ml with a median (IQR) of 19.4 (16.60–25.7) pg/ml, while its level in the control group ranged from 10.8 to 162.6 pg/ml with a median (IQR) of 20.2 (16.2–24.8) pg/ml. CT-1 levels showed no statistically significant difference between cases and controls. Patients had significantly higher mean left ventricle E/E′ ratio (p<0.001), lower mean 2D global longitudinal strain (GLS) of the left ventricle (LV) (p<0.001), and lower mean GLS of the right ventricle (RV) (p<0.001) compared to controls. Ofpatients with diabetes, 75 % had LV diastolic dysfunction, 85 % had RV diastolic dysfunction, 97.5 % had LV systolic dysfunction, and 100 % had RV systolic dysfunction. Conclusions: Non-conventional echocardiography is important for early perception of subclinical DCM in patients with T1D. CT-1 was not specific for early detection of DCM.
- Open Access
- 1 February 2023
- Published by Hindawi Limited in Journal of Interventional Cardiology
- Vol. 2023, 1-8
Staged Percutaneous Management of Pulmonary Atresia and Intact Interventricular Septum: Stretching the Limits
Aims. Pulmonary atresia with intact ventricular septum (PA/IVS) can be treated by catheter-based interventions and complemented by various surgical procedures. We aim to determine a long-term treatment strategy to enable patients to be surgery free, depending solely on percutaneous interventions. Methods and Results. We selected five patients from among a cohort of patients with PA/IVS treated at birth with radiofrequency perforation and dilatation of the pulmonary valve. Patients had reached a pulmonary valve annulus of 20mm or larger on their biannual echocardiographic follow-up, with right ventricular dilatation. The findings, together with the right ventricular outflow tract and pulmonary arterial tree, were confirmed by multislice computerised tomography. Based on the angiographic size of the pulmonary valve annulus, all patients were successfully implanted with either Melody® or Edwards® pulmonary valves percutaneously, regardless of their small weights and ages. No complications were encountered. Conclusion. We managed to stretch the age and weight limitations for performing percutaneous pulmonary valve implantation (PPVI): interventions were attempted whenever a pulmonary annulus size of >20mm was reached, which was rationalised by the prevention of progressive right ventricular outflow tract dilatation and accommodating valves between 24 and 26mm, which is enough to sustain a normal pulmonary flow in adulthood.
- 1 February 2023
- Published by Hindawi Limited in Journal of Interventional Cardiology
- Vol. 2023, 1-8
Open AccessStaged Percutaneous Management of Pulmonary Atresia and Intact Interventricular Septum: Stretching the Limits
Aims. Pulmonary atresia with intact ventricular septum (PA/IVS) can be treated by catheter-based interventions and complemented by various surgical procedures. We aim to determine a long-term treatment strategy to enable patients to be surgery free, depending solely on percutaneous interventions. Methods and Results. We selected five patients from among a cohort of patients with PA/IVS treated at birth with radiofrequency perforation and dilatation of the pulmonary valve. Patients had reached a pulmonary valve annulus of 20mm or larger on their biannual echocardiographic follow-up, with right ventricular dilatation. The findings, together with the right ventricular outflow tract and pulmonary arterial tree, were confirmed by multislice computerised tomography. Based on the angiographic size of the pulmonary valve annulus, all patients were successfully implanted with either Melody® or Edwards® pulmonary valves percutaneously, regardless of their small weights and ages. No complications were encountered. Conclusion. We managed to stretch the age and weight limitations for performing percutaneous pulmonary valve implantation (PPVI): interventions were attempted whenever a pulmonary annulus size of >20mm was reached, which was rationalised by the prevention of progressive right ventricular outflow tract dilatation and accommodating valves between 24 and 26mm, which is enough to sustain a normal pulmonary flow in adulthood.